In the last UK election in 2019, the NHS emerged as a major talking point, as the scale of the country’s support of the service was brought to the fore.
GSK's severe asthma therapy Nucala could find a new lease of life as a treatment for chronic obstructive pulmonary disease (COPD) after showing a clear benefit in a phase 3 trial.<